Advances in Heart Failure: A Year of Discovery - Moving Forward with SGLT2 Inhibitors

Published: 21 October 2020

  • Views:

    Views Icon 4955
  • Likes:

    Heart Icon 3

Overview

Full programme

  • Views:

    Views Icon 4955
  • Likes:

    Heart Icon 3

Overview

This programme focuses on assessing recent data on SGLT2 inhibitors that show they reduce CV outcomes, HF hospitalisations and mortality in HFrEF patients irrespective of T2DM .

 

The expert panel also discuss how new data from the EMPEROR-Reduced trial should be interpreted against complementary SGLT2 data and how these agents should be utilised in clinical practice.

Supported by an unrestricted educational service from Boehringer Ingelheim

Learning Objectives

  • Evaluate Emerging Data on the Treatment of Heart Failure with SGLT2 Inhibitors in Patients with or without T2DM
  • Compare SGLT2 Inhibitor Trial Data on the Treatment of Heart Failure in Patients with or Without T2DM.
  • Recall the Impact of Emerging SGLT2 Inhibitor Data in Heart Failure on Clinical Practice

Series overview

Part 1

SGLT2 inhibitors: Where Are We Now?

1 session

  • SGLT2 inhibitors: Where Are We Now?

    Watch now

Part 2

SGLT2 Inhibitors in HFrEF: EMPEROR-Reduced

1 session

  • SGLT2 Inhibitors in HFrEF: EMPEROR-Reduced

    Watch now

Part 3

SGLT2 Inhibitors in Context

1 session

Faculty biographies